Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free fatty acid (FFA) release from adipose tissue is a central metabolic process in which stored triglycerides within adipocytes are hydrolyzed, primarily during fasting or energy demand, to liberate FFAs and glycerol. These FFAs are then released into the circulation to serve as an energy source for other tissues such as muscle and liver. The process is tightly regulated by hormones like insulin (inhibits) and catecholamines (stimulates). Dysregulation of FFA release is implicated in various metabolic diseases, including insulin resistance, type 2 diabetes, and cardiovascular disease. Targeting pathways regulating FFA release holds therapeutic potential for treating these conditions.
Modulation of lipolysis via hormonal signaling (insulin inhibition, catecholamine stimulation). Targeting lipases (ATGL, HSL) or re-esterification pathways.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free Fatty Acid Release from Adipose Tissue (FFAR).